Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis.

BCL6 DLBCL in vivo xenograft inducible CRISPR/Cas9 lymphoma

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
03 Mar 2020
Historique:
received: 24 05 2019
accepted: 08 02 2020
entrez: 18 3 2020
pubmed: 18 3 2020
medline: 18 3 2020
Statut: epublish

Résumé

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphomas worldwide and is characterized by a high diversity of genetic and molecular alterations. Chromosomal translocations and mutations leading to deregulated expression of the transcriptional repressor BCL6 occur in a significant fraction of DLBCL patients. An oncogenic role of BCL6 in the initiation of DLBCL has been shown as the constitutive expression of BCL6 in mice recapitulates the pathogenesis of human DLBCL. However, the role of BCL6 in tumor maintenance remains poorly investigated due to the absence of suitable genetic models and limitations of pharmacological inhibitors. Here, we have utilized tetracycline-inducible CRISPR/Cas9 mutagenesis to study the consequences of BCL6 deletion in established DLBCL models in culture and

Identifiants

pubmed: 32180900
doi: 10.18632/oncotarget.27506
pii: 27506
pmc: PMC7061739
doi:

Types de publication

Journal Article

Langues

eng

Pagination

875-890

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST All authors except A. Ebert, A. Traunbauer, J. Jude, M. Hinterndorfer, M. Minnich and J. Zuber are employees of Boehringer Ingelheim. The main sponsor of the IMP is Boehringer Ingelheim. S.M. Blake was an employee of Boehringer Ingelheim now working for Astra Zeneca. No potential conflicts of interest were disclosed by the other authors.

Références

Blood. 2012 Nov 8;120(19):3986-96
pubmed: 22955915
Biochem Biophys Res Commun. 2017 Jan 8;482(2):310-316
pubmed: 27856253
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15018-23
pubmed: 12407182
N Engl J Med. 1994 Jul 14;331(2):74-80
pubmed: 8208268
Nat Immunol. 2013 Oct;14(10):1084-92
pubmed: 23974956
Blood. 2009 Apr 9;113(15):3397-405
pubmed: 18927431
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Cancer Cell. 2005 May;7(5):445-55
pubmed: 15894265
Cell Rep. 2015 Mar 3;10(8):1422-32
pubmed: 25732831
Nat Med. 2004 Dec;10(12):1329-35
pubmed: 15531890
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Oncotarget. 2016 Jan 19;7(3):3520-32
pubmed: 26657288
J Clin Invest. 2016 Sep 1;126(9):3351-62
pubmed: 27482887
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Bioorg Med Chem. 2017 Sep 1;25(17):4876-4886
pubmed: 28760529
Cell. 2013 Dec 19;155(7):1479-91
pubmed: 24360272
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10762-7
pubmed: 9380707
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
N Engl J Med. 1987 Nov 5;317(19):1185-9
pubmed: 3657890
Cancer Cell. 2010 Apr 13;17(4):400-11
pubmed: 20385364
Immunol Rev. 2012 May;247(1):172-83
pubmed: 22500840
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Blood. 2015 Nov 26;126(22):2466-74
pubmed: 26373676
Blood. 2007 Mar 1;109(5):1857-61
pubmed: 17105812
Neoplasia. 2017 Sep;19(9):661-671
pubmed: 28753442
Expert Opin Ther Targets. 2018 Feb;22(2):143-152
pubmed: 29262721
ACS Chem Biol. 2018 Nov 16;13(11):3131-3141
pubmed: 30335946
Cell Rep. 2017 Sep 19;20(12):2860-2875
pubmed: 28930682
Cancer Sci. 2019 Mar;110(3):926-938
pubmed: 30588718
Oncogene. 1998 Nov 12;17(19):2473-84
pubmed: 9824158
Blood Adv. 2018 Oct 23;2(20):2755-2765
pubmed: 30348671
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Cancer Invest. 2000;18(4):356-65
pubmed: 10808372
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Genome Res. 1998 Mar;8(3):186-94
pubmed: 9521922
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
J Med Chem. 2017 May 25;60(10):4386-4402
pubmed: 28485934
Nature. 2012 Jan 5;481(7379):90-3
pubmed: 22113614
Semin Diagn Pathol. 2011 May;28(2):167-77
pubmed: 21842702
J Med Chem. 2017 May 25;60(10):4358-4368
pubmed: 28471657
Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14198-203
pubmed: 15375218
Nature. 2011 Mar 10;471(7337):189-95
pubmed: 21390126
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
BMC Bioinformatics. 2016 Oct 21;17(1):428
pubmed: 27769170
J Clin Oncol. 2012 Oct 1;30(28):3452-9
pubmed: 22851565
EMBO J. 1995 Dec 15;14(24):6209-17
pubmed: 8557040
Nat Biotechnol. 2015 Apr;33(4):390-394
pubmed: 25690852
Nat Biotechnol. 2015 Jun;33(6):661-7
pubmed: 25961408

Auteurs

Stefanie Schlager (S)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Carina Salomon (C)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Sabine Olt (S)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Christoph Albrecht (C)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Anja Ebert (A)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Oliver Bergner (O)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Johannes Wachter (J)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Francesca Trapani (F)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Daniel Gerlach (D)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Tilman Voss (T)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Anna Traunbauer (A)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Julian Jude (J)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Matthias Hinterndorfer (M)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Martina Minnich (M)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.

Norbert Schweifer (N)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Sophia M Blake (SM)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Current address: AstraZeneca AB, Gothenburg, Sweden.

Vittoria Zinzalla (V)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Barbara Drobits (B)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Darryl B McConnell (DB)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Norbert Kraut (N)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Mark Pearson (M)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Johannes Zuber (J)

Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Medical University of Vienna, Vienna BioCenter (VBC), Vienna, Austria.

Manfred Koegl (M)

Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.

Classifications MeSH